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ABSTRACT
The buccal drug delivery system is a prominent route of administration for drug delivery through the buccal mucosa. It is rich in blood supply with 
more surface area for rapid absorption as well as provides direct entry of drugs from the site of application into the systemic circulation through the 
jugular vein. Buccal drug delivery systems consist of various approaches such as lozenges, wafers, gels, microparticles, patches or films from which 
mucoadhesive buccal film is an attractive dosage form in terms of flexibility and high systemic bioavailability. Since most of the antihypertensive 
drugs show first-pass metabolism which leads to less oral bioavailability generally up to 20–50%. Thus, incorporation of antihypertensive drugs 
in mucoadhesive buccal films using mucoadhesive polymers can provide higher systemic bioavailability. The films can be formulated using various 
techniques such as solvent casting method and hot extrusion melt method. These films can be evaluated based on various characteristics to determine 
their efficacy and performance such as tensile strength, mucoadhesion residence time, and kinetic release data analysis. They have various advantages 
over conventional solid oral dosage forms, hence are preferable for the preparation of antihypertensive drug-loaded buccal films. Mucoadhesive 
buccal films of antihypertensive drugs can also provide controlled drug delivery with enhanced bioavailability.
Keywords: Jugular vein, Bioavailability, Wafers, Mucoadhesive polymers.
INTRODUCTION
The buccal drug delivery system is the drug delivery system that 
emphasizes the drug administration through the mucosal membrane 
lining of the buccal cavity [1]. It acts as an attractive route of 
administration for the systemic delivery of drugs because of the rich 
vascularization of the buccal mucosa while also giving direct access 
to the drug through the jugular vein into the systemic circulation [2]. 
There are various approaches for the development of buccal drug 
delivery systems from which the mucoadhesive buccal films are more 
prominent and convenient for drug delivery. Buccal films are the dosage 
forms that involve hydration of water-soluble polymers to adhere and 
dissolve when applied between gums and cheeks, which can result in 
systemic drug delivery [2]. Hypertension is a condition in which blood 
pressure on the arteries is drastically elevated because of various factors 
(physiological and pathophysiological) [3]. Blood pressure is the force 
on the arteries when blood flows through blood vessels. Hypertension 
can be classified as primary hypertension (has an unknown cause) and 
secondary hypertension (has known cause) [3]. Majority of patients 
suffer from primary hypertension. Secondary hypertension is a result 
of various conditions that may affect vital organs such as kidney, 
heart, or endocrine glands. Blood pressure is measured as systolic 
blood pressure to diastolic blood pressure. The usual blood pressure 
of normal adults should be 120/80 mm of Hg while the patient 
suffering from hypertension shows blood pressure more than 140/90 
mm of Hg [4]. The drugs used for the treatment of hypertension are 
termed as antihypertensive drugs [5]. Antihypertensive drugs have 
various mechanisms to lower high blood pressure. Antihypertensive 
drugs are also used in the treatment of cardiovascular disorder such 
as myocardial infarction, cardiac arrhythmias, and cardiac strokes; 
kidney diseases such as chronic nephropathy [6]. Unfortunately 
administration of antihypertensive drugs through oral route shows 
less bioavailability up to 30–40% [6]. The major factor responsible 
for the delayed bioavailability of antihypertensive drugs is hepatic 
first-pass metabolism [7]. The inclusion of drug in the buccal films, 
avoids the hepatic first-pass metabolism leading to high systemic 
bioavailability [7]. Thus, buccal films can be a prominent alternative 
for the administration of antihypertensive drugs than other oral 
dosage forms.
PATHOPHYSIOLOGY OF HYPERTENSION
Physiologically, hypertension is a condition in which the blood pressure 
is elevated above the normal value, that is, 140/90 mm of Hg. In 
clinical terms, blood pressure can be referred to as the pressure in 
arteries produced by left ventricle after ventricular contraction and the 
pressure in arteries by remaining blood in ventricles during ventricular 
relaxation [8]. The blood pressure is measured as the systolic blood 
pressure to diastolic blood pressure. Systolic blood pressure is the force 
of blood pressure on arterial walls just after ventricular contraction 
whereas diastolic blood pressure is the force exerted by the blood 
remaining in the arteries during ventricular relaxation [9]. The normal 
blood pressure reading is 140/90 mm Hg. Hypertension can be classified 
as essential (primary or idiopathic) hypertension and secondary 
hypertension [9]. Essential hypertension is a very common type of 
hypertension with an unknown cause which accounts for 95% of all 
cases of hypertension [10]. While secondary hypertension has known 
cause which may be a result of any physiological or pathophysiological 
factors, accounts for 5% of all cases of hypertension [10]. There are 
various factors responsible for elevating blood pressure which results 
in hypertensive conditions. The major factors are as follows,
Cardiac output and peripheral vascular resistance 
Normal blood pressure can be maintained through a balance between 
cardiac output and peripheral vascular resistance [9]. Patients with 
primary hypertension show normal cardiac output but increased 
peripheral vascular resistance. Peripheral vascular resistance is 
determined by small arterioles present on the walls of smooth muscles. 
Hence, it can be concluded that the contraction of smooth muscles due 
to a rise in intracellular calcium can lead to an increase in peripheral 
resistance [5,9]. Thus, it may explain vasodilator action of calcium 
channel blockers in the hypertensive state [6]. While prolonged 
contractions of smooth muscle can lead to structural damage to 
arteriolar vessels possibly triggered by angiotensin, which may result 
© 2021 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/
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in an irreversible elevation in peripheral resistance. Clinically due to 
hypersecretion of epinephrine and norepinephrine (may be caused 
by a tumor in adrenal medulla) shows positive inotropic and positive 
chronotropic effects, leading to increased total peripheral resistance [8].
Overactivation of resin-angiotensin-aldosterone (RAA) system
RAA system helps in the homeostasis for maintaining blood pressure 
in the body by regulating the secretion of aldosterone [9]. Some 
physiological conditions such as dehydration, sodium(Na+) deficiency, 
or hemorrhage, and blood volume gets decreased which eventually 
results into drop in normal blood pressure [9]. This drop in blood 
pressure triggers the juxtamedullary cells of the kidney to secrete renin 
in the blood resulting in increase in renin concentration in the blood. In 
liver, renin converts angiotensinogen (inactive) to angiotensin I. Further 
angiotensin I is converted into angiotensin II (active) by angiotensin-
converting enzyme (ACE) in the lungs. Angiotensin II works in two 
ways to regulate blood pressure [11]. First, angiotensin II stimulates 
the contraction of smooth muscles of vascular arterioles which 
increases the blood pressure to a normal state. Second, angiotensin II 
triggers the adrenal cortex to release aldosterone (glucocorticoid which 
maintains the salt and water reabsorption). Aldosterone increases the 
reabsorption of Na+ which, in turn, causes the reabsorption of water 
by osmosis [11]. This helps to maintain the blood volume by limiting 
the water loss through urine. Aldosterone also increases the secretion 
of K+ & H+ ions into the urine which are then excreted [11]. Sometimes 
obstruction of renal blood flow or disorders that damages renal tissues 
may cause the kidney to secrete excessive amounts of renin into the 
blood. Thus resulting in an increasing amount of angiotensin II which 
leads to increased systemic vascular resistance by vasoconstriction of 
arterioles [8]. This may explain the function of angiotensin II receptor 
inhibitors in the treatment of hypertension [4]. Due to abnormalities in 
the adrenal cortex, the secretion of aldosterone is increased drastically 
which leads to excessive reabsorption of salts and water. Thereby the 
blood pressure is raised to an abnormal state. Thus, it can explain the 
function of aldosterone inhibitors in the treatment of hypertension [5].
Endothelial dysfunction OR Endothelial injury 
The vascular endothelial layer has its unique role in the maintenance 
of blood pressure to the normal state [5]. They can produce the 
various potent locally acting vasoactive agents. It includes nitric acid 
(NO) (vasodilator) and peptide endothelin (vasoconstrictor). Hence, 
endothelial dysfunction or endothelial injury has to be considered while 
the treatment of hypertension [9]. Thus, modulation of the endothelial 
function should be considered as an essential factor for minimizing 
hypertension. Clinically, the use of nitroglycerides as vasodilators can 
be the primary treatment of hypertension by restoring the impaired 
production of nitric oxide thus enabling normal function again [9].
Endocrine system
In condition such as dehydration or decreased blood pressure, the 
baroreceptors in the brain get triggered. These stimuli allow the 
hypothalamus to produce an antidiuretic hormone (ADH) and it is 
released from the posterior region of the pitutory gland into the 
bloodstream [9]. ADH causes the vasoconstriction of arterioles and 
veins in the skin which elevates the blood pressure to a normal state, 
while ADH also promotes the reabsorption of water from renal tubules 
into the bloodstream to increase the blood volume by decreasing urine 
output. Abnormalities in the functioning in hypothalamus region may 
cause the overproduction of ADH which leads to excessive stimulation 
of ADH receptors in kidneys [8]. This may produce the hypertensive 
state due to overactivation of ADH receptors. Hence, the antidiuretic 
receptor antagonists can help in the treatment of hypertension [6,11]. 
BUCCAL FILMS
Buccal films are the laminar structure that consists of a drug-polymer 
solution layer with other excipients, an impermeable backing layer, 
and a bioadhesive surface for attachment to the buccal mucosa [12]. 
There are two types of designs for the manufacturing of buccal films, 
that is, matrix type and reservoir type [13]. Matrix type buccal films 
involve the dispersion of drug into a matrix polymer solution which 
provides controlled drug release. While reservoir type buccal films 
consist of a space or cavity for a drug-polymer solution in which drug is 
dissolved, which is separated from bioadhesive [13]. An impermeable 
backing layer is used to control the direction of drug release and 
to avoid unnecessary multidirectional drug release as it prevents 
drug loss [14]. The buccal epithelium layer is the main barrier to the 
transport of drugs through the buccal mucosa [12]. Drug transport 
from buccal mucosa can be either paracellular or transcellular 
transport [13-15]. Paracellular transport (also called as intercellular 
transport) is defined as the transport of drugs through the junctions 
between mucosal epithelial cells [15]. While transcellular transport 
(also called intracellular transport) is defined as the transport of the 
drug across mucosal epithelium, which is the most common pathway 
for drug transport [15]. Highly lipophilic drugs and macromolecules 
permeate buccal mucosa through passive transcellular transport 
whereas lipophilic compounds and small hydrophobic molecules 
predominantly pass through paracellular transport [15]. The drug 
transport is also depended on the permeation enhancers used in 
buccal films. They have a different mechanism for the transport of 
drugs through mucosal cell lining [16].
ADVANTAGES
High patient compliance
The painless administration of dosage form which is considered as 
one of the major advantages of the buccal films [13]. The ease of 
application makes it patient friendly. Patients can control the period 
of administration or termination emergencies, without any special 
assistance. The parenteral route of administration is associated 
with pain; hence, buccal films can be more convenient for children 
and elderly patients [12,17-19]. It also does not need chewing and 
swallowing of the dosage form. Mostly elderly patients suffer from 
hypertension so sometimes it is not feasible to administer conventional 
solid oral dosage forms for such patients and hence buccal films can be 
preferred due to their ease of application [7]. 
Increased systemic bioavailability 
The buccal mucosa is rich in vascular intervention for direct access of 
drug into systemic circulation through jugular vein as well as it provides 
a large mucosal surface for absorption [16]. This can provide enhanced 
systemic bioavailability for poorly absorbed drugs than conventional 
dosage forms. As most of the antihypertensive drugs possess less 
bioavailability given the fact of their high hepatic first-pass metabolism 
when administered through the oral route and hence to overcome 
this problem buccal films may be an attractive route for delivery of 
antihypertensive drugs [7,20-23].
Rapid onset of action
Buccal mucosa provides a rich blood supply for local drug absorption 
from the buccal cavity hence is advantageous [1,12]. Thus, it gives the 
rapid onset of action in a short period of time. Ideally, antihypertensive 
drugs should have a rapid onset of action but when it goes through the 
oral route, it takes time for absorption which leads to the slow onset 
of action [16]. This slow onset of action is not feasible in emergencies 
where the patient is unconscious. Therefore, buccal films can be a 
substitute dosage form for conventional one to provide antihypertensive 
drugs with rapid absorption through rapid transport of drugs through 
buccal mucosa into the systemic circulation [7].
Protection from GI degradation 
Drugs that are liable for acid degradation in the stomach can be 
administered by buccal drug delivery system [24]. This route of 
administration can avoid drug loss by stomach acid degradation. It also 
reduces the GI side effects of antihypertensive drugs such as vomiting 
and nausea. Some of the antihypertensive drugs such as beta-blockers 
show extensive metabolism by CYP450 enzymes in the intestine leading 
to the inactivation of an active drug or active drug metabolite [19]. 
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Hence, buccal films can be used to surpass GI degradation for the 
delivery of antihypertensive drugs [7,20-21].
LIMITATIONS
Not feasible for high dose drugs
Buccal films have limited drug loading capacity with a polymer solution, 
as a high dose can lead to saturation of drug at the site of application. 
Drugs can be incorporated into a single dose of 20 mg or less. Thus, 
buccal films are not feasible for the drugs having a single high dose, that 
is, more than 20 mg [25]. However, most of the antihypertensive drugs 
have single-dose less than 20 mg which makes them an ideal candidate 
for API for buccal films [7]. Therefore, the delivery of antihypertensive 
drugs can be possible in the form of buccal films.
Not applicable for mucosa irritating drugs
Some drugs such as 5-fluorouracil and methotrexate show the irritation 
to the mucosal membrane, thus not accessible for the formulation of 
buccal films [7]. Mucosal irritation can lead to damage to mucosal cell 
lining or any allergic reaction. However, most of the antihypertensive 
drugs do not show any prominent evidence of mucosal irritation in the 
buccal cavity [26]. Thus, buccal films can be used for the delivery of 
antihypertensive drugs.
Dilution of the drug by saliva
In the buccal cavity, the saliva is continuously secreted through salivary 
glands [12]. However, due to some physiological conditions which favor 
the excessive secretion of saliva, leads to dilution of the drug at a site 
of action where the buccal film is applied [13,24]. Sometimes excessive 
salivation can lead to lead to detachment of film from its site and 
swallowing of the film can also be one of the possible cases. This lead to 
loss of drug, as it goes into the stomach with saliva [25].
Composition of mucoadhesive buccal films
Buccal films require very few excipients as compared to other buccal 
drug delivery systems. Buccal films include active pharmaceutical 
ingredients (APIs), mucoadhesive polymer, and other excipients.
API
From any class of pharmacology drugs, any drug can be used for 
buccal administration but it should be compatible with buccal 
mucosa [27,28]. API should not show irritation as they can lead to 
mucosal layer damage in the buccal cavity. Different types of API 
can be efficiently incorporated in the buccal film. Drugs having high 
solubility and high permeability (BCS I) having a low dose can be the 
best candidate for buccal administration. Other class of drugs (BCS 
II, III, or IV) requires the prior treatment such as micronization and 
solid dispersion to enhance either solubility or permeability or both, 
before incorporating into the film [29]. The dose of a drug should be 
in milligrams (mg) (less than 20 mg/day) for effective treatment. The 
drug can be incorporated from 5%–30% w/w of the total weight of the 
polymer in the buccal film [12,13,30]. Drugs having a single high dose 
are difficult to incorporate into the buccal film. As antihypertensive 
drugs require less dose for effective pharmacological action, they can be 
efficiently incorporated into the films.
IDEAL PROPERTIES FOR A DRUG TO BE INCORPORATED INTO 
BUCCAL FILMS
The dose should be lower than 20 mg [25].
It does not have any significant mucosal irritation.
It should be stable in water and saliva [24].
It should show the ability to permeate the buccal mucosal layer.
Mucoadhesive polymer
For the development of a buccal delivery system, the mucoadhesive 
polymer is considered as one of the major formulation components of 
the system [12]. These polymers help to provide the intimate contact 
between dosage form, that is, buccal film and biological membrane, that 
is, buccal mucosal layer [24]. When these buccal films are applied in 
the buccal cavity, they attract water to hydrate the film and to provide 
a strong interaction between the film and the mucosal layer hence 
allowing for the drug to release [14,24].
Mucoadhesion by polymers happen in two stages [14]
Stage I (contact stage)
Either setting, spreading, or swelling of mucoadhesive polymer produces 
the close contact between the polymer and mucosal membrane.
Stage II (consolidation stage)
Water provides the moisture to break the molecules and helps to form 
the attractive interaction bonding between polymer and membrane 
with reduced repulsive interaction bonding.
Ideal properties of a mucoadhesive polymer are described as follows,
1. Non-toxic and safe
2. Chemically inert
3. It should have good mechanical strength [28]
4. Compatible with saliva including its components [25]
5. It should provide immediate mucoadhesion to the buccal 
mucosa [17,25,27]
6. Compatible with API and other excipients [1].
The classification of mucoadhesive polymers with respect to its origin 
is described in Table 1.
The release kinetic profile of the drug from the polymer structure matrix 
depends on the morphology of polymer and its characteristics [34]. The 
mechanisms of the drug release from polymer can either by simple 
diffusion from polymer or degradation of polymer or both [14,15]. 
The polymer degradation takes place either by salivary enzymes or 
by hydrolysis. There are two types of polymer erosion, that is, surface 
erosion and bulk erosion [15,34]. Surface erosion is the degradation 
of the polymer starting from its surface either by hydrolytic or by 
enzymatic cleavage and bulk erosion is the degradation from the inside 
of the polymeric system when water penetrates the bulk of polymer 
mostly by hydrolytic cleavage reactions [15].
The examples of mucoadhesive polymers used in buccal films of 
antihypertensive drugs as shown in Table 2.
Permeation enhancers 
For the development of the buccal delivery system, membrane 
permeation is considered as the limiting factor [13,24]. Thus, the 
study of permeation through the buccal route is essential because it 
is fundamental for the selection of proper permeation enhancers to 
improve the drug permeability. Since BCS III and IV drugs show low 
permeability, thus with the help of permeation enhancers the problem 
of permeability can be overcome [36,48]. The various classes of 
permeation enhancers used in buccal films are given in Table 3.






1. Natural Sodium alginate, Tragacanth, 
Guar gum, Xanthan gum, 
Gelatin, Lectins, Pullulan, 
Maltodextrin, Chitosan, Pectin, 
Starch and modified starch
[1,14,25,31,34-35] 
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Table 2: Mucoadhesive polymers used in buccal films of 






1. Metoprolol EC and HPMC
EC and chitosan 
[7]
2. Methyldopa HPMC K47 [37]








6. Candesartan HPMC K4M [41]






8. Losartan HPMC K15M [43]
9. Furosemide HPMC E464 [44]
10. Nifedipine Sodium alginate [45]
11. Carvedilol Chitosan & Pectin [46]
12. Verapamil HCl Chitosan [47]
Table 3: Permeation enhancers used in buccal films described in the literature
S. No. Type Examples References
1. Surfactants ANIONIC: Sodium lauryl sulfate, sodium dodecyl sulfate, Dioctyl sodium sulfosuccinate
CATIONIC: Chitosan, Trimethyl chitosan, Cetylpyridinium chloride, L-lysine, 
Poly-L-arginine, Benzalkonium bromide
NON-IONIC: Tween 80, Polysorbates, Polyoxyethylene-9-lauryl ether, 
Polyoxyethylene-9-cetyl ether, Poloxamer, brij, Span, Myrj
[1,4,27,48]
2. Derivatives of fatty acids Oleic acid, Caprylic acid, Sodium caprate, Propylene glycol, Methyl oleate, lauric acid, 
linoleic acid, acylcholine, lysophosphatidylcholine, phosphatidylcholine, acylcarnitine
[1,21,36,48]
3. Derivatives of bile salts Sodium taurocholate, Sodium deoxycholate, Sodium glycocholate, Sodium 
glycodeoxycholate, Sodium taurodeoxycholate, Sodium taurodihydrofusidate
[1,14,36,48]
4. Chelating agents EDTA, Citric acid, Methyl salicylate, Methoxy salicylates [1,14,36,48]
5. Non-surfactants Unsaturated cyclic ureas, Urea and it’s derivatives, Azone [1,36,48]
6. Sulfoxides Dimethyl sulfoxide, Decylmethyl sulfoxide [1,14,36,48]
7. Inclusion complexes Cyclodextrin [14,28,36]
8. Thiolated polymers Chitosan-4-thiobutylamide, Chitosan-4-thiobutylamide/GSH, Chitosan-cysteine, 
Poly-(acrylic acid)-homocysteine, Polycarbophil-cysteine, Polycarbophil-cysteine/GSH
[27,48]
9. Monohydric acids Ethanol, Methanol, Isopropanol [13,48,52]
10. Polyhydric acids Propylene glycol, Polyethylene glycol, Glycerol, Propanediol [14,48]
11. Others Aprotinin, Dextran sulfate, various alkyl glycosides, Polyvinylpyrrolidone, Menthol [14,52]
Permeation enhancers interact with the buccal mucosal layer to deliver 
the drug from a buccal film into the systemic circulation [14,16]. They 
should be non-toxic, non-irritant, and chemically inert. They should not 
have any pharmacological action. The action of permeation enhancers 
on the buccal mucosal layer should be reversible [36,48]. So that after 
absorption of the drug, the epithelium of buccal mucosa should again 
retain their barrier properties [49-51]. The examples of permeation 
enhancers used in antihypertensive drug loaded buccal films are given 
in Table 4.
Plasticizers 
Plasticizers are used to reduce the fragility of mucoadhesive buccal 
films as well as for better flexibility and strength of the film. Plasticizers 
can be incorporated in the film from concentration 0–20% w/w of the 
dry polymer weight [14,27]. The selection of plasticizers depends on 
properties of drugs and mucoadhesive polymer used [13]. The action 
of plasticizer is to avoid the polymer-polymer interaction as it goes in 
between every individual polymer strand [27,54]. This helps to overcome 
the problem of polymer deformation. Plasticizer also affects the release 
of the drug from the film [27]. Examples of plasticizers used in the buccal 
film include glycerol, low molecular weight polyethylene glycol, phthalate 
derivatives such as dimethyl and diethyl phthalate, and citrate derivatives 
such as tributyl, triethyl, acetyl citrate, triacetin, and castor oil [27,55].
Sweetening agents
The compounds which provide the sweet taste are called as sweetening 
agents or sweeteners. Sweeteners have been very important 
excipient for the formulation as they provide a pleasant taste to the 
product [1,13,14,54]. Low molecular weight carbohydrates such 
as glucose, fructose, sucrose, and dextrose are generally used as 
sweeteners in pharmaceutical products [14,25]. Nowadays, artificial 
sweeteners have gained the focus as an alternative sweetener in 
the pharmaceutical industry [25]. Sweeteners are used alone or in 
combination from concentration 2% to 6% w/w of the dry weight of 
the film [12]. Other than common sweeteners, alternative sweeteners 
which can be used in buccal films are given in Table 5.
Saliva stimulating agent (Saliva stimulator)
Saliva helps in the disintegration and dissolution of buccal films [56]. 
This leads to drug release from buccal film to the mucosal layer for 
further absorption process [56]. Saliva stimulating agents aids in the 
production of an excess amount of saliva to increase the disintegration 
of the film leading to a quick release of drugs from the buccal 
film [12]. Mostly acids are used as saliva stimulators in the formulation 
as they trigger the immediate production of excess saliva in the buccal 
cavity [20]. Examples of saliva stimulants are citric acid, maleic acid, 
lactic acid, Vitamin C (ascorbic acid), and tartaric acid [12,25,27]. They 
can be used in buccal film alone or in combination from concentration 
2% to 6% w/w dry weight of the film [12,25].
Flavoring agents 
Flavoring agents are used to masking the taste of bitter drugs [27]. 
Thus, flavoring agents are needed to enhance the flavor and mouth-feel 
effect in the buccal film [25]. In buccal film formulations, preferably 
up to 10% w/w flavor is allowed [14]. Flavors can be used alone or in 
combination according to the formulation requirements. The different 
types of flavorings agents with examples are given in Table 6.
Sometimes flavoring agents also show the cooling effect with their 
significant flavor. It makes the formulation more fresh and pleasant. An 
examples of such a flavoring agents are menthol, monomethyl succinate 
which have an additional cooling effect [14].
Coloring agent (colorant)
To make the film more attractive, coloring agents are incorporated 
into the buccal films [12]. The concentration of colorant in the film 
should not exceed more than 1% w/w of the dry weight of the film [14]. 
There is various approved range of colors available that includes FD & 
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Table 4: Permeation enhancers used in buccal films of 
antihypertensive drugs described in the literature 








Sodium lauryl sulfate 
[40]
2. Methyldopa PVP K-30 [38]
3. Candesartan Propylene glycol [41]
4. Losartan Propylene glycol [49]
5. Valsartan Propylene glycol [42]
6. Enalapril maleate PVP [53]
Table 5: Different types of alternative sweeteners
S. No. Type of sweetener Description of sweetener Examples References
1. Nutritive sweetener They are less caloric and sweet than sugar but have 
most of the properties like sugars. Thus they are 
also used as a bulking agent in sugar-free products.





They are sweeter than sugar and required in least 
quantities.
Fruit sugars, Aspartame, Sodium saccharin, 
Glycyrrhizin, Stevioside, Cyclamate
[14,25]
3. Artificial sweetener They are prepared synthetically and now commonly 
used as they are less carcinogenic.
Aspartame, Sodium saccharin, Sorbitol, 
Mannitol, Acebilfame-K
[14,25]
4. Natural sweetener They are extracted from plant or animal origin. Plant: Glycyrrhizin, Neohesperidine, Stevioside
Animal: Honey, Lactose from cow milk
[14,25]
C colors, EU colors, natural colors or pigments, metal oxides such as 
titanium oxide, zinc oxide, and so forth [24,25].
METHODS OF PREPARATION
Mucoadhesive buccal films can be prepared by following methods-
1. Solvent casting method
2. Hot melt extrusion (HME) method.
Solvent casting method
The solvent casting method is the most widely accepted manufacturing 
process utilized for the production of films [12]. It is a very simple and 
easy method which makes it a more conventional method than other 
methods. In this method, the required quantity of polymer is dissolved in 
distilled water. On the other hand, active pharmaceutical ingredients and 
other excipients are dissolved in a suitable solvent system. Afterward, 
both solutions are mixed and stirred to form a homogeneous mixture. 
This resultant solution is called as “casting solution.” The casting solution 
is then diffused on the Petri dish and kept in a hot air oven for drying at 
the optimum temperature (mostly 40°C). After drying, that Petri plate is 
kept in a desiccator for 24 h. Afterward, the dried film is removed from 
the Petri dish and cut into the required dimensions [25].
The solvent casting method involves the steps which are described 
below [25,58-63],
•	 Step 1: Preparation of casting solution
•	 Step 2: Deaeration of casting solution
•	 Step3: Transfer of deaerated casting solution into the mold
•	 Step 4: Drying of the solution
•	 Step 5: Cutting of dried film into appropriate dimensions 
•	 Step 6: Packaging of formed films
Deaeration is considered as the most critical step of the solvent casting 
method. If the films are formed in a solution that has entrapped air in 
it then it leads to surface non-uniformity as well as uneven thickness of 
the film. One of the major disadvantages of the solvent casting method 
is the presence of organic solvent impurities in the films [25]. One of 
the examples of the mucoadhesive buccal film of the antihypertensive 
drug prepared by the solvent casting method is buccoadhesive polymer 
matrix films of Losartan using HPMC polymer [49].
HME method
HME is one of the techniques which involve the molecular dispersion 
of drug (API) into a polymer matrix [63]. This method includes the 
instrument called as hot melt extruder [13]. In this method, the drug 
and polymer are fed into hopper and passed it to an extruder. In the 
extruder, the drug and polymer with other excipients are mixed, 
ground, and heated to form a homogeneous molten mixture. This 
mixture is then kneaded and went through an orifice to mold under 
specified pressure and temperature to shape the films. The formed 
product is cooled and packed in suitable packaging material [63-65]. 
This method does not involve any use of a solvent which makes it a 
solvent-free method. It also provides better uniformity of contents 
than the solvent casting method [25]. The two major limitations of 
this method include only limited polymers that can be used and it is 
not suitable for thermolabile molecules such as proteins which might 
degrade [25,64]. Examples of film-forming agents that can be used in 
HME are polyethylene oxide, maltodextrin, hydroxypropyl cellulose 
(HPC), hydroxypropylmethylcellulose (HPMC), pullulan, starch, and 
modified starch, etc. [64]. One of the examples of a mucoadhesive 
buccal film of the antihypertensive drug prepared by hot-melt extrusion 
method is cellulosic hot-melt extruded films containing Lidocaine using 
HPC and HPMC polymer [66].
CHARACTERIZATION OF MUCOADHESIVE FILMS
The mucoadhesive buccal films should be evaluated to determine 
their quality and efficiency. There are various tests to be performed to 
characterize the buccal films which are described below-
Physical appearance and surface texture
(Evaluation of organoleptic properties)
Organoleptic properties such as color, flavor, and taste should be 
primarily evaluated. It is mainly done by visual inspection of prepared 
buccal films. The errors in manufacturing processes can lead to defects 
in buccal film formulation. This may include defects in the surface 
texture of films. An uneven surface of buccal films is the indication of 
non-uniformity of contents and fault in developed films. Good taste, 
color, and surface texture provide more patient accessibility. The taste 
of the film can be determined using E-tongue software [14,67,68].
Surface pH
Inappropriate surface pH of the buccal film can lead to irritation of buccal 
mucosa in vivo. Therefore, the determination of surface pH is considered 
as one of the important evaluation parameters. The pH of the buccal 
mucosa is around pH 6.2–7.5. Thus, buccal film should also have the pH 
range as that of the pH of buccal mucosa to avoid mucosal irritation. In 
this method, the film is placed in the petri dish and 0.5 ml of distilled 
water is put on the surface of the film and kept it for 1.0 h. Then, the pH is 
measured by touching the electrode tip of pH-meter in contact with the 
moistened surface of the buccal film for about 1.0 min [14,69-71].
Wettability
The wettability of the film is determined by the measurement of the contact 
angle. As contact angle affects the wetting property, disintegration, and 
dissolution time of the film. A special instrument with a digital camera is 
used to determine the contact angle. A drop of bidistilled water is placed 
on the surface of the film for few seconds at ambient conditions. Then, 
further analysis for determination of contact angle is done by software. 
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To obtain well-defined results, a minimum of twenty measurements 
should be performed for each film formulation [14,72].
Transparency
The optical property of the buccal film is determined by measuring 
transparency using a UV-visible spectrophotometer. The film is directly 
placed in the spectrophotometer magnetic cell and an empty cell is 
kept as a reference. Transparency of film is determined by measuring 
transmittance at 660 nm [14,73]. Transparency is calculated using 
formula-
Transparency= (T660/b) = -εc 
Where, T660 is transmittance at 660 nm, b is film thickness, c is 
concentration, and ε is molar absorptivity
Swelling index
Here, the pre-weighted dry film is kept in a Petri dish containing 
phosphate buffer pH 6.6 at 37°C for a pre-determined time (t). The film 
will be swelled. After time “t,” the film is separated from phosphate-
buffered solution (PBS) and wiped with absorbent tissue paper to 
remove an excess of water from the surface. Then, swelled film is 
reweighted [13-14,28,74,75]. The swelling index is determined using 
formula-
S.I. = [(W2-W1)/W1]×100
Where, S.I. is swelling index of film, W2 is weight of swollen film at time 
“t,” W1 is weight of dry film at zero time
Percent erosion of polymer
The erosion characteristics of films are determined by measuring 
the erosion of the polymer. Here, the dry film is kept in a Petri dish 
containing simulated saliva for a pre-determined time (t). The polymer 
will undergo erosion processes. After time “t,” the remaining film is 
removed from the Petri dish, dried, and weighed again [53]. The percent 
erosion of polymer is determined using formula-
% erosion = [(W1-W2)/W1] ×100
Where, W1 is original weight of dry film at zero time and W2 is remaining 
weight of film at time “t”
Thickness
The buccal film should have a uniform and optimum thickness with a 
range of 5–200 μm. Proper thickness ensures the accurate dose and 
good absorption of the drug. Thickness can be measured either using an 
electronic digital micrometer screw gauge or calibrated digital Vernier 
caliper. To determine the thickness, different positions such as four 
corners and the center of a film should be considered [13,14,67,77].
Weight variation
The optimum sized films are cut from different positions of casting film. 
The individual films are weighed using electronic weighing balance and 
the average weight is calculated. The weight variation is calculated by 
subtracting the average weight of the film from the individual weight of 
the film. The large weight variation indicates improper method and also 
non-uniform content in the film [12,14,78,79].
Percent moisture loss
Percent moisture loss is an indication of film integrity and physical 
stability. The accurately weighed films are kept in a desiccator containing 
fused anhydrous calcium chloride for 3 days leading to moisture loss. 
After 3 days, the films are taken out and weighed again [14,84,85]. The 
percent moisture loss can be determined using formula-
% moisture loss= [(W1-W2)/W1] ×100
Where, W1 is initial weight of dry film and W2 is final weight of film
Percent moisture absorption
The pre-weighted films are kept in desiccator having 100 ml of a 
saturated solution of ammonium chloride up to 96% humidity for 
72 h. After 72 h, films are removed and weighed again [14,86,87]. The 
percent moisture absorption is determined using formula-
% moisture absorption= [(W2-W1)/W1] ×100
Where, W1 is initial weight of dry film and W2 is final weight of film
Folding endurance
Folding endurance is considered as a measure of the brittleness of film. 
It is done by repeatedly folding optimum sized (generally 2×2 cm2 or 
3×3 cm2) film under standard conditions until it breaks or visible crack 
observed [13,14,83,88].
Tear resistance
Tear resistance is considered to measure maximum resistance offered 
by the film at a rate up to 50 mm/min before the rupturing of the film 
when load or force is applied. It is performed either using Elmendorf 
tear tester (pendulum method) or in the tensile testing machine [14,82].
Tensile strength
Tensile strength is the maximum stress or force applied to rupture the 
film by stretching. The film is placed between the clamps lever of the 
instrument and additional force at a rate of 2 mm/min was applied to 
film [14,73,90-92]. At tearing time, a load of failure (F) is measured.
Tensile strength= [F/(t×w)]×100
Where, F is weight or load of failure, t is thickness of film and w is width 
of film
The hard and brittle film has high tensile strength [14].
Percent elongation
Elongation capacity of the film is expressed by stretching capacity after 
applying stress to deform the film before it gets broken [14,80]. The 
percent elongation is calculated using formula-
% elongation= [(L2-L1)/L1] ×100
Where, (L2-L1) is increased length of film and L1 is initial length of film
Interaction study
Drug-polymer-excipient interactions should be considered while 
characterization for the development of an effective buccal film. It is 
done either using the FTIR spectrometer using the KBr pellet method 
to record the FTIR spectrum or by differential scanning calorimetry to 
record thermograms of sample films [14,81].
Drug content uniformity
It is done by dissolving the buccal film in 100 ml of an appropriate 
solvent system for complete solubilization of film with occasional 
shaking. From that solution, 5 ml of solution is withdrawn and diluted 
using a pre-determined solvent system to form a final resultant 
solution. This resultant solution is filtered through Whatman filter 
paper and analyzed using analytical techniques such as HPLC, HPTLC, 
and LC-MS [14,56,86].
Table 6: Different types of flavors
S. No. Type of flavor Examples References
1. Essential oils Peppermint, Sweet mint, 
Wintergreen, Menthol 
[14,25,27]
2. Citrus fruit flavor Lemon, Orange [14,25,27]





Asian J Pharm Clin Res, Vol 14, Issue 4, 2021, 12-21
 Yelave and Bhagwat
XRD study
XRD analysis is done to determine the physical form, that is, crystalline or 
amorphous of drug molecules inside the films. It is performed on an X-ray 
diffractometer to record XRD transmission diffractogram (XRD patterns) 
over the diffraction angle range of 2θ at a scan rate of 4°/min [31].
Scanning electron microscopy (SEM) analysis
Analysis of outer surface morphology of buccal film is done by SEM 
using a scanning electron microscope with appropriate applied voltage. 
It also helps to determine drug-excipient interactions [14,93].
In vitro disintegration time study
For better absorption, the buccal film should disintegrate in the oral 
mucosa. In vitro disintegration time test has been described in USP. The 
film is placed in a Petri dish containing 10–15 ml of PBS having pH 6.6. 
Then, the Petri dish is kept in an incubator shaker at a speed of 50 rpm 
at 37°±1°C. The time at which the film starts to break is recorded as 
disintegration time [14,84,86].
In vitro dissolution study
Dissolution test apparatus type II (USP II) (Paddle type) is used to study 
the in vitro drug release profile using isotonic PBS pH 6.6 at 50 rpm at 
37°±1°C for time period of 8 h [94]. The film is pasted to a glass disk 
with cyanoacrylate adhesive. This assembly is placed at bottom of the 
dissolution flask. The flask is filled with 900 ml PBS pH 6.6. The sample 
(aliquot) of 5 ml is taken out at regular intervals and replaced with fresh 
PBS pH 6.6. Then, the aliquot is filtered, diluted with PBS pH 6.6 and 
analyzed by spectrophotometer [14,76,81].
Kinetic release data analysis
Various kinetic models such as the zero-order, the first order, the 
Higuchi, the Hixon-Crowell cube root law, and the Korsmeyer–Peppas 
model are used to analyze the drug release mechanism from the 
buccal films. The readings of dissolution data are put in the respective 
mathematic models to determine the drug release kinetics [25].
In vitro metabolism studies
The development of cell culture models for the study of drug metabolism 
is in process. In the literature, they had attempted with hamster cheek 
cultured cells as hamster cheek cells narrowly mimic human mucosa 
cells which make it a suitable model for prediction of permeability 
through the human buccal mucosa [89].
Ex vivo mucoadhesion test/ residence test 
The efficiency of mucoadhesive buccal films is dependent on how 
much time it is able to adhere or stick to the buccal mucosa where 
the film is subjected before it dissolves or deteriorates away. For the 
particularly sustained release of a drug, it is expected that the film 
remains at the site of application until the maximum drug is released. 
The mucoadhesion time of the buccal film is the time required for the 
film to detach or erode from freshly excised porcine buccal mucosa 
(model membrane) onto which the buccal film is applied. The film is 
moistened with simulated saliva solution and placed on buccal mucosa. 
Then with little force for about 10–20 s, the initial contact between 
the film and mucosal membrane is generated on the left pan. In the 
right pan, drop wise water is added until the film is detached from the 
mucosal membrane. The weight of water in the right pan is considered 
as bioadhesive strength. The average of bioadhesive strength of three 
buccal films is considered for further calculation [41,42,46,49,95-97]. 
The mucoadhesive force can be determined by a formula-
Mucoadhesive force= (Bioadhesive strength/1000) ×9.81 
Ex vivo mucoirritation test
It is done to observe the pathological changes in buccal cell membrane 
morphology and their structure after the application of buccal films. 
It is performed by using a freshly excised bovine buccal mucosal 
membrane. The sample film is prepared with eosin pigment and cut in 
a thickness of 4 μm. The sample film without the drug is considered as 
a controlled group while sample film with the drug as a treated group. 
Then a photograph of controlled untreated and drug-containing buccal 
film subject to simple diffusion in the bovine buccal mucosal membrane 
as observed [42].
Ex vivo permeation study
The permeation studies of buccal films through a freshly excised layer 
of sheep buccal mucosa are carried out using modified Franz diffusion 
cell. In the donor compartment, the film is wetted with PBS pH 6.6 and 
placed in contact with a buccal mucosal membrane and filled with 
5 ml of PBS pH 6.6. The receptor compartment is filled with isotonic 
PBS pH 6.6 and stirred using a magnetic stirrer at ambient conditions 
with a speed of 50 rpm. The samples (1 ml) are collected at suitable 
time intervals, filtered, diluted with PBS pH 6.6, and then analyzed by 
a suitable analytical method to determine the percent drug permeated 
through the buccal mucosa [14,41,98,99].
In vivo study
Since in vitro testing lacks the systemic evaluation and the effect of other 
physiological factors on the overall performance of active ingredient 
from the buccal film. In general, an in vivo study is first performed on 
animal models such as rats, rabbits, dogs, and pigs before testing on 
humans. The blood samples are withdrawn at regular intervals and 
centrifuged to get a plasma sample. The plasma is filtered and diluted 
with an appropriate solvent. Then, it is analyzed using a suitable 
analytical technique such as the HPLC system [46].
Stability study in human saliva
It is done using natural human saliva. The human saliva samples of 
10 healthy volunteers (18-40 years age group) are collected. The film 
is placed in a Petri dish containing 5 ml of human saliva and kept it at 
ambient conditions. At regular intervals, the morphology and organoleptic 
properties of the buccal film are observed. If no physical change in the film 
is observed, then it indicates the film will be more stable in the buccal 
cavity throughout the period of its residence time [14,73,82-84,86].
Stability study as per ICH guidelines
As per ICH guidelines for the stability of the formulation, the films 
are kept at 40°C and 75% relative humidity to observe the effect of 
temperature and humidity on buccal films for 3 months. At the time 
of 1st, 2nd, and 3rd months, the films are observed for drug content by 
performing drug assay as well we for investigation in a specific change 
in prepared films which includes a change in color and texture. If 
non-complied assay and specific changes are observed, the films are 
subjected to stability issues in storage conditions [14,83,84,86].
EXAMPLES OF MUCOADHESIVE BUCCAL FILMS CONTAINING 
ANTIHYPERTENSIVE DRUGS
Carvedilol hydrochloride
Carvedilol is from the β-blocker class of drugs used for the treatment 
of hypertension by reducing the total peripheral resistance. Carvedilol 
hydrochloride shows 25–35% of bioavailability on oral administration 
due to its high hepatic first-pass metabolism. Thus, an approach of 
administration of carvedilol through buccal film had been performed by 
Amanpreet Kaur et al. to overcome the problems. They had developed 
buccal patches of carvedilol HCl using natural polymers (chitosan and 
pectin) as mucoadhesive polymer showing improved bioavailability. 
They concluded that using interpolymers complex of chitosan and 
pectin can be used to formulate the buccal films of carvedilol [46].
Nitrendipine
Nitrendipine is from calcium channel blockers class of drugs used for 
the treatment of hypertension. Since nitrendipine shows extensive 
hepatic first-pass metabolism on oral administration causing 10–15% 
bioavailability. As an alternative to oral administration, the approach of 
nitrendipine in buccal films had been carried out by Nappinnai et al. to 
get better results. They had prepared buccal films of nitrendipine using 
HPC as a mucoadhesive polymer having better bioavailability than 
conventional solid oral dosage forms [100].
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Valsartan
Valsartan is an angiotensin II receptor antagonist class of drugs 
used in the therapy of hypertension. Valsartan undergoes high 
first-pass metabolism leading to low oral bioavailability of 20–
25%. To overcome the problem, an attempt for the development 
of mucoadhesive buccal films of valsartan had been performed by 
Rani and Madhavi. They had developed the buccal film of valsartan 
using natural polymer, that is, jackfruit gum to provide sustained 
release formulation with better bioavailability. They concluded that 
the bioerodable buccal films can be used for the effective delivery of 
active agent with prominent IVIVC [42].
Enalapril maleate
Enalapril is the ACE inhibitor class of drugs used in the treatment 
of hypertension. Enalapril maleate shows 60–70% absorption but 
40–30% oral bioavailability. The low bioavailability is a result of high 
hepatic first-pass metabolism. Thus formulation of the mucoadhesive 
buccal film of enalapril maleate had been performed by Semalty et al. 
using sodium carboxymethylcellulose and hydroxyethylcellulose as 
mucoadhesive polymers to enhance the bioavailability and effective 
treatment [53].
Furosemide
Furosemide is the loop diuretic class of drugs used in the management 
of hypertension as it inhibits reabsorption of sodium, chloride, and 
potassium ions with increased urine flow. Furosemide belongs to BCS 
Class IV drugs, thus it shows low solubility and low permeability. In 
literature, Alopaeus et al. had attempted to develop a mucoadhesive 
buccal film of furosemide using Soluplus® (a mixture of PEG 600, vinyl 
caprolactam and vinyl acetate) as a solubilizer and the film-forming 
agent showing enhanced absorption and bioavailability by ex vivo 
permeation studies using TR146 epithelial cell linings [44].
CONCLUSION
The approach of mucoadhesive buccal films has been provided various 
advantages for the administration of antihypertensive drugs to 
minimize the problem of low bioavailability and GI degradation. Various 
antihypertensive drugs have been incorporated into mucoadhesive 
buccal films to provide effective management of hypertension. An 
antihypertensive drug with different excipients is used to formulate and 
develop mucoadhesive buccal films using different techniques. These 
buccal films are characterized by various evaluation tests to estimate 
the quality, efficiency, and performance through mucoadhesive delivery 
of proposed buccal films. Through literature, it has been seen that 
various mucoadhesive buccal films containing antihypertensive drugs 
are developed with improved absorption and bioavailability.
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